Immix Biopharma (IMMX) Total Liabilities (2020 - 2026)

Immix Biopharma (IMMX) has 7 years of Total Liabilities data on file, last reported at $11.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 11.2% year-over-year to $11.5 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (up 11.2% YoY), and the FY2025 full-year result was $11.0 million, up 13.9% from the prior year.
• Total Liabilities climbed to $11.5 million in Q1 2026, from $11.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $11.8 million in Q3 2025 to a low of $365086.0 in Q1 2022.
• A 5-year average of $5.8 million and a median of $4.9 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 765.33% in 2022 and increased 11.2% in 2026, its largest moves.
• Tracing IMMX's Total Liabilities over 5 years: stood at $1.7 million in 2022, then soared by 112.88% to $3.7 million in 2023, then surged by 160.54% to $9.7 million in 2024, then climbed by 13.9% to $11.0 million in 2025, then rose by 3.69% to $11.5 million in 2026.
• Business Quant data shows IMMX's Total Liabilities at $11.5 million in Q1 2026, $11.0 million in Q4 2025, and $11.8 million in Q3 2025.